Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Andrographolide attenuates bupivacaine-induced cytotoxicity in SH-SY5Y cells through preserving Akt/mTOR activity.

Tytuł:
Andrographolide attenuates bupivacaine-induced cytotoxicity in SH-SY5Y cells through preserving Akt/mTOR activity.
Autorzy:
Zhang H; Department of Neurology, Liaocheng People's Hospital, Liaocheng, Shandong, 252000, People's Republic of China.
Wang W; Department of Neurology, Liaocheng People's Hospital, Liaocheng, Shandong, 252000, People's Republic of China.
Du Q; EEG Room, Liaocheng People's Hospital, Liaocheng, Shandong 252000, People's Republic of China.
Źródło:
Drug design, development and therapy [Drug Des Devel Ther] 2019 May 16; Vol. 13, pp. 1659-1666. Date of Electronic Publication: 2019 May 16 (Print Publication: 2019).
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: [Auckland, N.Z.] : Dove Press Limited
MeSH Terms:
Antineoplastic Agents/*pharmacology
Apoptosis/*drug effects
Bupivacaine/*antagonists & inhibitors
Diterpenes/*pharmacology
Proto-Oncogene Proteins c-akt/*metabolism
TOR Serine-Threonine Kinases/*metabolism
Antineoplastic Agents/chemistry ; Antioxidants/metabolism ; Bupivacaine/pharmacology ; Cell Proliferation/drug effects ; Diterpenes/chemistry ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Molecular Structure ; Oxidative Stress/drug effects ; Structure-Activity Relationship ; Tumor Cells, Cultured
References:
Br J Pharmacol. 2002 Jan;135(2):399-406. (PMID: 11815375)
J Neurosurg Anesthesiol. 2004 Jan;16(1):108-10. (PMID: 14676583)
Biochem Pharmacol. 2004 Apr 1;67(7):1337-45. (PMID: 15013849)
J Immunol. 2004 Sep 15;173(6):4207-17. (PMID: 15356172)
J Dent Res. 2005 Sep;84(9):852-7. (PMID: 16109997)
Neurotoxicology. 2010 Jan;31(1):101-12. (PMID: 19879292)
Pharmacology. 2011;87(3-4):121-9. (PMID: 21304223)
Eur J Pharmacol. 2011 Apr 25;657(1-3):51-8. (PMID: 21315711)
Paediatr Anaesth. 2011 Jul;21(7):716-21. (PMID: 21466608)
Can J Anaesth. 2012 May;59(5):456-65. (PMID: 22383086)
BMC Neurosci. 2012 Dec 10;13:149. (PMID: 23227925)
Oxid Med Cell Longev. 2013;2013:159864. (PMID: 24228138)
Pharmacol Biochem Behav. 2014 Jul;122:191-202. (PMID: 24726706)
Nan Fang Yi Ke Da Xue Xue Bao. 2015 Aug;35(8):1133-6. (PMID: 26277509)
Proteomics. 2016 Feb;16(4):564-75. (PMID: 26621341)
Int J Clin Exp Med. 2015 Sep 15;8(9):15065-75. (PMID: 26628990)
Neural Plast. 2015;2015:935403. (PMID: 26798521)
Oxid Med Cell Longev. 2016;2016:6143753. (PMID: 26989453)
Braz J Anesthesiol. 2016 May-Jun;66(3):272-5. (PMID: 27108824)
Neurochem Res. 2016 Sep;41(9):2425-32. (PMID: 27233246)
Int J Mol Sci. 2016 Jun 09;17(6):. (PMID: 27294913)
Environ Toxicol. 2017 Mar;32(3):918-930. (PMID: 27297870)
Cell Biochem Funct. 2016 Aug;34(6):455-62. (PMID: 27558076)
Molecules. 2017 Feb 06;22(2):. (PMID: 28178193)
Oxid Med Cell Longev. 2017;2017:8539026. (PMID: 28751934)
Biomed Res Int. 2017;2017:4210867. (PMID: 29085837)
Sci Rep. 2017 Nov 6;7(1):14520. (PMID: 29109537)
Eur J Pharmacol. 2018 Aug 15;833:63-68. (PMID: 29802833)
Inflammation. 2018 Oct;41(5):1681-1689. (PMID: 29948505)
J Cell Physiol. 2018 Jan;234(1):561-571. (PMID: 30071128)
Front Neurosci. 2018 Sep 20;12:657. (PMID: 30294256)
J Exp Clin Cancer Res. 2018 Oct 12;37(1):248. (PMID: 30314513)
Front Microbiol. 2018 Oct 08;9:2407. (PMID: 30349523)
J Cell Biochem. 2018 Oct 28;:null. (PMID: 30368886)
Thorac Cancer. 2019 Mar;10(3):492-500. (PMID: 30666790)
Contributed Indexing:
Keywords: Akt; andrographolide; apoptosis; bupivacaine; cytotoxicity
Substance Nomenclature:
0 (Antineoplastic Agents)
0 (Antioxidants)
0 (Diterpenes)
410105JHGR (andrographolide)
EC 2.7.1.1 (MTOR protein, human)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
EC 2.7.11.1 (TOR Serine-Threonine Kinases)
Y8335394RO (Bupivacaine)
Entry Date(s):
Date Created: 20190614 Date Completed: 20200120 Latest Revision: 20211204
Update Code:
20240104
PubMed Central ID:
PMC6529178
DOI:
10.2147/DDDT.S201122
PMID:
31190744
Czasopismo naukowe
Background: Bupivacaine (Bup) is the most commonly used local anesthetic. However, Bup induces cytotoxicity, especially in older patients. Recent reports have indicated that andrographolide (Andro) exhibits protective effects on human neurons. Nevertheless, whether Andro can inhibit Bup-induced cytotoxicity remains unclear. As such, we investigated the effect of Andro on Bup-induced cytotoxicity of SH-SY5Y cells in the present study. Methods: Western blotting was used to examine expression of Bax, Bcl2, active caspase 3, p-Akt, and p-mTOR in SH-SY5Y cells. In addition, ELISA was used to detect levels of total glutathione and reactive oxygen species in cells. Results: We found that Andro attenuated Bup-induced cytotoxicity of SH-SY5Y cells. In addition, Andro inhibited Bup-induced apoptosis via downregulating the expression of Bax and active caspase 3 and upregulating the proteins Bcl2, p-Akt, and p-mTOR in SH-SY5Y cells. Moreover, Andro alleviated Bup-induced oxidative damage in SH-SY5Y cells via downregulating the level of reactive oxygen species and upregulating of the level of total glutathione. More significantly, inhibition of Akt abolished the protective effect of Andro in Bup-treated SH-SY5Y cells. Conclusion: Our findings indicated that Andro played a neuroprotective role via preserving Akt/mTOR activity and increasing antioxidative status in Bup-treated SH-SY5Y cells. Therefore, Andro may be a potential agent for the treatment of human cytotoxicity induced by Bup.
Competing Interests: The authors report no conflicts of interest in this work.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies